Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate

Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
M PecherstorferB Bergström

Abstract

To compare the efficacy and safety of ibandronate and pamidronate in patients with hypercalcemia of malignancy (HCM). Seventy-two patients with HCM [albumin-corrected serum calcium (CSC) >2.7 mmol/l] were treated with a single infusion of ibandronate (2 or 4 mg) or pamidronate (15, 30, 60, or 90 mg) on day 0. The dose was dependent on the severity of hypercalcemia (baseline CSC level). CSC was assessed daily until day 4, then at intervals until day 28. The primary endpoint was lowering of CSC at day 4. Secondary endpoints included the number of patients responding and time to re-increase following response. Using the CSC baseline approach, the most frequently administered doses were 4 mg ibandronate (78.4%) and 60 mg pamidronate (50.0%). Mean lowering of CSC at day 4 was 0.6 mmol/l for ibandronate and 0.41 mmol/l for pamidronate. The 95% confidence interval for the difference ibandronate pamidronate had a lower limit of 0.05 mmol/l, indicating that ibandronate was as effective as pamidronate. The number of patients responding to the two agents was also similar; 76.5% of ibandronate patients and 75.8% of pamidronate patients were rated as responders after the first dose of study medication. The median time to re-increase after r...Continue Reading

Citations

Nov 8, 2011·Rheumatology International·Kun-Juan ZhangDong-Gang Liu
Sep 17, 2004·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·M Pecherstorfer, I J Diel
Apr 13, 2004·Clinical Oncology : a Journal of the Royal College of Radiologists·M Clemons
Jan 28, 2005·The New England Journal of Medicine·Andrew F Stewart
Feb 27, 2013·Journal of Social Work in End-of-life & Palliative Care·Maria WasnerGian Domenico Borasio
Nov 30, 2007·Clinical Interventions in Aging·Philip Sambrook
Dec 21, 2004·Expert Review of Anticancer Therapy·Axel Heidenreich, Carsten H Ohlmann
Mar 5, 2011·Critical Reviews in Oncology/hematology·Evangelos TerposJames Berenson
Aug 13, 2010·Seminars in Oncology·James R Berenson
Dec 12, 2007·Best Practice & Research. Clinical Haematology·Heinz Ludwig, Niklas Zojer
Dec 30, 2015·North American Journal of Medical Sciences·Aibek E Mirrakhimov
Jun 29, 2005·Emergency Medicine Clinics of North America·John Sarko
Aug 27, 2013·Orvosi hetilap·Ildikó RadványiSándor Balogh
Sep 8, 2011·Current Opinion in Endocrinology, Diabetes, and Obesity·Gregory A Clines
Nov 30, 2007·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Karin Olson, Catherine Van Poznak
Mar 26, 2011·Journal of Intensive Care Medicine·Michael A ViaJeffrey I Mechanick
Mar 10, 2005·The Annals of Pharmacotherapy·Angelo A Licata
Apr 8, 2017·Mayo Clinic Proceedings·Thorvardur R HalfdanarsonBo E Madsen
Aug 31, 2004·Palliative Medicine·Y SaundersUNKNOWN Steering Group
Apr 28, 2009·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Atthapon JaishuenJohn J Kavanagh
Mar 21, 2006·Annals of Oncology : Official Journal of the European Society for Medical Oncology·T Tanvetyanon, P J Stiff
Aug 11, 2012·Clinical Journal of the American Society of Nephrology : CJASN·Mitchell H Rosner, Alan C Dalkin
Jul 20, 2005·Hospital Medicine·R A Hubner, S J Houston
Apr 11, 2012·Cancer Control : Journal of the Moffitt Cancer Center·Rachel L Theriault, Richard L Theriault
Apr 11, 2012·Cancer Control : Journal of the Moffitt Cancer Center·L S LoftusG H Sokol
Nov 29, 2017·Der Internist·S Krug, P Michl
Jan 31, 2006·Arquivos brasileiros de endocrinologia e metabologia·Maria Lucia F de Farias
May 13, 2009·Clinical Drug Investigation·Bruno FredianiGiovanni Cremonesi
Nov 30, 2020·British Journal of Haematology·Evangelos Terpos, Ioannis Ntanasis-Stathopoulos
Dec 8, 2020·Journal of the National Comprehensive Cancer Network : JNCCN·Shaji K KumarRashmi Kumar

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.